AgingResearch.NewsJoin free

OLX10212

OLX10212 has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 10, 2026: “RNA compound reduced abnormal blood vessel lesions in mice”.

Intervention

1 paper studies it6 findingsUpdated

See all 1 papers on OLX10212

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country; 1 trial, none about aging, 1 with no results posted.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

About aging: the drug’s trials about aging. The total counts its trials for every use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 1 trial, none about aging, 1 with no results posted
  • 6 of 6 findings with company ties
  • 1 of 1 trial sponsored by its developers
  • Animals1

What did studies of OLX10212 find?

5

Studies of OLX10212 measured 5 outcomes, among them choroidal neovascularization lesion volume, NLRP3 and corneal epithelial injury.

Choroidal neovascularization lesion volume

downin cynomolgus monkeys1downin mice1

1 study

  1. OLX10212 decreases choroidal neovascularization lesion volume in cynomolgus monkeys (laser-induced choroidal neovascularization model).

    “A single intravitreal dose reduced lesion volume in laser-induced choroidal neovascularization models in mice and cynomolgus monkeys.”

    Animalslaser-induced choroidal neovascularization modelpalmitoyl-conjugated cell-penetrating asymmetric siRNAchoroidsingle intravitreal dose

    RNA compound reduced abnormal blood vessel lesions in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

  2. OLX10212 decreases choroidal neovascularization lesion volume in mice (laser-induced choroidal neovascularization model).

    “A single intravitreal dose reduced lesion volume in laser-induced choroidal neovascularization models in mice and cynomolgus monkeys.”

    Animalslaser-induced choroidal neovascularization modelpalmitoyl-conjugated cell-penetrating asymmetric siRNAchoroidsingle intravitreal dose

    RNA compound reduced abnormal blood vessel lesions in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

NLRP3

downin animals1

1 study

  1. OLX10212 decreases NLRP3 (sodium iodate- and Alu RNA-induced geographic atrophy models).

    “suppressing NLRP3-associated transcripts, consistent with the inhibition of inflammasome signaling”

    Animalssodium iodate- and Alu RNA-induced geographic atrophy modelspalmitoyl-conjugated cell-penetrating asymmetric siRNAretina

    RNA compound reduced abnormal blood vessel lesions in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

More on NLRP3

Corneal epithelial injury

downin animals1

1 study

  1. OLX10212 decreases corneal epithelial injury (benzalkonium chloride-induced dry eye disease model).

    “Topical administration further ameliorated corneal epithelial injury and inflammatory cytokine expression in a benzalkonium chloride-induced DED model.”

    Animalsbenzalkonium chloride-induced dry eye disease modelpalmitoyl-conjugated cell-penetrating asymmetric siRNAcornea

    RNA compound reduced abnormal blood vessel lesions in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

VEGF expression

downin mice1

1 study

  1. OLX10212 decreases VEGF expression in mice.

    “Vascular endothelial growth factor (VEGF) expression was also decreased in mice”

    Animalspalmitoyl-conjugated cell-penetrating asymmetric siRNA

    RNA compound reduced abnormal blood vessel lesions in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

More on VEGF expression

Retinal degeneration

downin animals1

1 study

  1. OLX10212 protects against retinal degeneration (sodium iodate- and Alu RNA-induced geographic atrophy models).

    “OLX10212 preserved retinal architecture and electroretinographic function”

    Animalssodium iodate- and Alu RNA-induced geographic atrophy modelspalmitoyl-conjugated cell-penetrating asymmetric siRNAretina

    RNA compound reduced abnormal blood vessel lesions in mice

    Molecular therapy : the journal of the American Society of Gene Therapy

More on Retinal degeneration

Who is developing OLX10212?

1 company: Olix Pharmaceuticals.

Companies
  • Olix PharmaceuticalsPhase 1neovascular age-related macular degeneration

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months
Molecular Therapy

RNA compound reduced abnormal blood vessel lesions in mice

A single injection into the eye reduced lesion volume in a laser-induced mouse model of abnormal blood vessel growth.A single injection into the eye reduced lesion volume in a laser-induced mouse model of abnormal blood vessel growth.

Mouse studyInterventions
Paper

Related